Teva appears to have altered plans to launch in the near future its generic version of Amarin’s Vascepa (icosapent ethyl), despite entering into a settlement agreement with the originator more than three years ago opening the door for market entry.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?